Selecting an Appropriate Treatment Regimen for Patients With HR+/HER2- mBC

Dr Virginia Kaklamani explains how she selects among the available treatment regimens for her patients with HR+/HER2= metastatic breast cancer.

Related Keywords

,Virginia Kaklamani ,Breast Cancer ,Hr Her2 Metastatic Breast Cancer ,Mbc ,Hr Her2 Mbc ,Metastatic Breast Cancer ,Clinical Practice ,Ut Health San Antonio ,Adcs ,Endocrine Resistance ,Premenopausal ,Postmenopausal ,Metastatic Breast Cancer Chemotherapy ,Hr Her2 Metastatic Breast Cancer Treatments ,